Consequently, GATA-3 expression was significantly associated with poor outcomes following the administration of conventional chemotherapeutic agents in PTCL, NOS and in a genetically engineered mouse (GEM) model. The gene discussed is GATA3; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.